Remember that person on here back in 21/22 that said our company crested on Udenyca? That the biosim to an already outdated eye drug was a total boondoggle from the get-go? That guy was right, and that guy was me. I'm going for the trifecta when our 7th to market pd1 Loqtorzi fails to achieve meaningful numbers by mid Q3/early Q4. Maybe then I'll be awarded consulting fees for my predictions. I'll need it, because meaningful bonus achievement with these products is impossible.
